The R01 is the currency of academic clinical research — it's what separates an investigator who's "running a trial" from one who's actually funded to do it properly. The June 2026 cycle operates under the same payline pressures as every cycle in recent years, but the clinical trial-specific requirements have grown substantially more burdensome since NIH tightened its definition of what constitutes a "clinical trial" in 2017. If you haven't done a clinical trial R01 recently, the Human Subjects sections alone will surprise you. This guide covers the June 5, 2026 deadline specifically — payline context, the CTR designation trap that kills applications at intake, and what study sections consistently criticize in clinical trial submissions.
This article is for research investigators and institutional administrators. It does not constitute legal or regulatory advice. Verify all requirements with your institution's Office of Research and the NIH program officer for your specific application.
Deadline Alert
NIH R01 standard due date for new applications: June 5, 2026. Clinical trial R01s require additional lead time — IND/IDE status, IRB approval plan, and DSMB arrangements must all be addressed in the application. Start Human Subjects sections now.
Summary
The R01 Research Project Grant funds the overwhelming majority of investigator-initiated clinical trials at NIH — Phase I through Phase III, plus observational research involving human participants. Clinical trial R01s use the same June 5, 2026 standard deadline as basic science applications, but the complexity is categorically different. You're not just writing a Research Strategy; you're simultaneously building a regulatory compliance framework, a recruitment feasibility case, and a safety monitoring plan — all of which require institutional coordination that basic science investigators simply don't face. Three to four weeks minimum for Human Subjects alone. Start now.
The CTR Designation Problem That Kills Applications at Intake
Here's where investigators get in trouble before a single reviewer reads their science. NIH defines a clinical trial in a way that is broader than most investigators assume — it's not just randomized controlled trials. If your study involves human participants, you're assigning an intervention, and you're measuring a health-related biomedical or behavioral outcome, NIH almost certainly classifies it as a clinical trial. Submitting that application to a "Clinical Trial Not Allowed" (CTNA) FOA gets it rejected without review. Doesn't matter how good the science is.
The Clinical Trial Requirement (CTR) designation must match the FOA you choose. Use NIH's Clinical Trial Decision Tool at grants.nih.gov before you pick your FOA — not after you've written 25 pages of Significance and Innovation. Contact the Program Officer for the relevant Institute and confirm your study meets their specific FOA requirements. This conversation takes fifteen minutes and can save months of work on a misdirected application.
What Study Sections Actually Score on Clinical Trial R01s
Having reviewed study section critiques across multiple cycles, the patterns are consistent. Reviewers are not simply evaluating whether the science is interesting — they're evaluating whether this specific team can actually execute this specific trial. Those are different questions, and many applications conflate them.
- Recruitment feasibility is the most common fatal weakness. Saying you have access to a clinic with 3,000 patients with the relevant condition is not enough. Reviewers want documented referral relationships, site experience in trial enrollment, and a realistic accrual projection — with monthly numbers, not just total sample size. If you've run a prior study at that site, cite your actual enrollment rates. If you haven't, explain who has and why they're co-investigators.
- Power calculations need to be clinically anchored. A power calculation derived from a single small pilot study will get flagged. Reviewers want to see the MCID (Minimum Clinically Important Difference) for your primary endpoint, justified from the literature, and a sample size calculation that would survive if your pilot effect size was inflated by 30%. Inflate-adjusted sensitivity analyses are now expected in most study sections.
- DSMB plans that lack specifics. "We will establish a DSMB" is not a DSMB plan. Name potential members, specify the monitoring schedule, define the stopping rules for safety and futility, and describe the statistical boundaries (O'Brien-Fleming, Lan-DeMets, etc.) you'll use for interim analyses. Phase II trials need this as much as Phase III.
- Team qualifications under scrutiny. Does the PI have a track record of completed trials? Is there a dedicated biostatistician with trial experience — not just someone who "can analyze data"? Is there clinical research coordinator infrastructure that has enrolled human subjects before? Reviewers check CVs for trial execution history, not just publication lists.
- IND/IDE ambiguity. Applications that say "we will determine if an IND is needed" rather than demonstrating they've already worked through this question are asking for a concern. FDA pre-IND meetings take 2–3 months to schedule; reviewers know this timeline and will note if your application doesn't reflect it.
Required Sections Unique to Clinical Trial R01s
- Protection of Human Subjects: For a clinical trial, this section is substantive — IRB approval status or plan, recruitment and consent procedures, assessment of risks and benefits, data confidentiality measures, and special population protections if applicable. Budget three to four weeks minimum.
- Inclusion of Women, Minorities, and Children: Enrollment plans must be justified or demonstrate compliance with NIH's inclusion policies. Exclusion of any group requires scientific justification — reviewers are increasingly skeptical of convenience-based exclusions that result in homogeneous trial populations.
- Data Safety Monitoring Plan: Phase II and III trials require a full DSMB plan. Phase I trials require at minimum a description of stopping rules and safety review procedures. The DSMP must specify who makes safety decisions and on what timeline.
- Single IRB designation: Multi-site trials funded by NIH after January 2020 must use a single IRB of record. This requires institutional agreement and coordination before submission — it cannot be retroactively established after award.
- Dissemination Plan: Clinical trial R01s require a plan for disseminating results, including ClinicalTrials.gov reporting timelines. NIH has been increasingly enforcing reporting requirements; the dissemination plan is reviewed as part of the application, not just noted as a checkbox.
Timeline: What to Be Doing Right Now
- Immediately: Confirm your study's clinical trial status using the NIH Decision Tool. Contact the IC Program Officer. Identify your FOA and confirm it's still open for the June cycle.
- Now through mid-April: Begin Human Subjects sections. Initiate IRB pre-submission contact if IRB approval isn't already in hand. Confirm IND/IDE status with institutional regulatory affairs. Identify DSMB candidates.
- April through mid-May: Draft and iterate Research Strategy with study section-specific critique in mind. Complete power and sample size sections with clinical anchoring. Write DSMB and DSMP in detail.
- Late May: Submit to your institution's grants office for sign-off — budget five to seven business days for institutional review. Large clinical trial applications generate substantial administrative complexity; coordinate early.
- June 5, 2026: Submission deadline. Confirm receipt in eRA Commons within 48 hours. Any system issues must be reported to NIH on the day they occur.
Key Deadlines
- June 5, 2026 — New R01 standard due date (Clinical Trial Required)
- July 5, 2026 — A1 resubmission due date
- ~October 2026 — Study Section review meetings for June submissions
- ~December 2026 — Summary Statements released for June submissions
- October 5, 2026 — Next new R01 standard due date